Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 26, 2022; 10(30): 11162-11171
Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.11162
Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.11162
Longest survival with primary intracranial malignant melanoma: A case report and literature review
Tang-Fai Wong, Department of Neurosurgery, Macao Kiang Wu Hospital, Macao 999078, Sichuan Province, China
Tang-Fai Wong, Yin-Sheng Chen, Xiang-Heng Zhang, Zhong-Ping Chen, Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Wan-Ming Hu, Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Xiao-Shi Zhang, Department of Biotherapy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Yan-Chun Lv, Dong-Cun Huang, Department of Medical Imaging, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong Province, China
Mei-Ling Deng, Department of Radiotherapy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Author contributions: Chen YS, Hu WM, Lv YC, Huang DC, and Deng ML designed and performed the research content; Wong TF, Zhang XH, and Chen ZP wrote the paper; all authors wrote, read, and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.
Conflict-of-interest statement: All authors declare no direct conflict of interest for this work.
CARE Checklist (2016) statement: All authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhong-Ping Chen, MD, PhD, Chief Doctor, Neurosurgeon, Professor, Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng East Road, Yuexiu District, Guangzhou 510060, Guangdong Province, China. chenzhp@sysucc.org.cn
Received: July 2, 2022
Peer-review started: July 2, 2022
First decision: August 1, 2022
Revised: August 10, 2022
Accepted: September 7, 2022
Article in press: September 7, 2022
Published online: October 26, 2022
Processing time: 110 Days and 20.9 Hours
Peer-review started: July 2, 2022
First decision: August 1, 2022
Revised: August 10, 2022
Accepted: September 7, 2022
Article in press: September 7, 2022
Published online: October 26, 2022
Processing time: 110 Days and 20.9 Hours
Core Tip
Core Tip: Primary intracranial malignant melanoma (PIMM) is quite rare, and its prognosis is poor. Comprehensive treatment, including the surgical resection and the maintenance of postoperative adjuvant treatments by Newcastle disease virus-modified tumor vaccine, interferon, and β-elemene may prolong patient survival. We hope that the PIMM case reported in this paper, which describes a patient whose life was extended by 22 years, can provide useful information for the reference of medical practitioners and patients alike, thereby boosting their confidence in adopting the treatment reported herein.